RU2015103190A - METHOD FOR ASSESSING THE RISK OF PROGRESSING INTRAEPITITAL CERVICAL NEOPLASIA AND THE DEVELOPMENT OF Cervical Cancer ON THE BASIS OF DETERMINING HUMAN GENE mRNA LEVELS - Google Patents
METHOD FOR ASSESSING THE RISK OF PROGRESSING INTRAEPITITAL CERVICAL NEOPLASIA AND THE DEVELOPMENT OF Cervical Cancer ON THE BASIS OF DETERMINING HUMAN GENE mRNA LEVELS Download PDFInfo
- Publication number
- RU2015103190A RU2015103190A RU2015103190A RU2015103190A RU2015103190A RU 2015103190 A RU2015103190 A RU 2015103190A RU 2015103190 A RU2015103190 A RU 2015103190A RU 2015103190 A RU2015103190 A RU 2015103190A RU 2015103190 A RU2015103190 A RU 2015103190A
- Authority
- RU
- Russia
- Prior art keywords
- expression level
- progression
- development
- risk
- cervical
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 11
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract 9
- 201000010881 cervical cancer Diseases 0.000 title claims abstract 9
- 108020004999 messenger RNA Proteins 0.000 title claims abstract 9
- 230000009826 neoplastic cell growth Effects 0.000 title claims abstract 9
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 5
- 238000000034 method Methods 0.000 title claims abstract 3
- 230000002250 progressing effect Effects 0.000 title 1
- 230000014509 gene expression Effects 0.000 claims abstract 15
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims abstract 4
- 108091012583 BCL2 Proteins 0.000 claims abstract 4
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims abstract 4
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims abstract 4
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 claims abstract 4
- 231100000504 carcinogenesis Toxicity 0.000 claims abstract 4
- 230000010309 neoplastic transformation Effects 0.000 claims abstract 4
- WVAKRQOMAINQPU-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]pyridine Chemical compound N1C(CC(C)(C)CC)=CN=C1CCC1=CC=C(C=2N=CC=CC=2)C=C1 WVAKRQOMAINQPU-UHFFFAOYSA-N 0.000 claims abstract 2
- 102100027308 Apoptosis regulator BAX Human genes 0.000 claims abstract 2
- 108050006685 Apoptosis regulator BAX Proteins 0.000 claims abstract 2
- 102000004000 Aurora Kinase A Human genes 0.000 claims abstract 2
- 108090000461 Aurora Kinase A Proteins 0.000 claims abstract 2
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 claims abstract 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims abstract 2
- 102100038595 Estrogen receptor Human genes 0.000 claims abstract 2
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims abstract 2
- 101000740062 Homo sapiens BAG family molecular chaperone regulator 1 Proteins 0.000 claims abstract 2
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims abstract 2
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 claims abstract 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims abstract 2
- 101000979748 Homo sapiens Protein NDRG1 Proteins 0.000 claims abstract 2
- 102100025136 Macrosialin Human genes 0.000 claims abstract 2
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 claims abstract 2
- 102100024980 Protein NDRG1 Human genes 0.000 claims abstract 2
- 108010002687 Survivin Proteins 0.000 claims abstract 2
- 230000006907 apoptotic process Effects 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 230000022131 cell cycle Effects 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 230000003902 lesion Effects 0.000 claims abstract 2
- 230000036210 malignancy Effects 0.000 claims abstract 2
- 230000035755 proliferation Effects 0.000 claims abstract 2
- 108020003175 receptors Proteins 0.000 claims abstract 2
- 102000005962 receptors Human genes 0.000 claims abstract 2
- 101150077745 ex gene Proteins 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Способ оценки риска прогрессирования интраэпителиальной цервикальной неоплазии и развития рака шейки матки на основе определения уровней мРНК генов человека, отличающийся тем, что измеряют уровень мРНК генов человека MKI67, CDKN2A или используют любые другие маркеры пролиферации и регуляции клеточного цикла, изменение уровня экспрессии которых при прогрессировании интраэпителиальной цервикальной неоплазии и развитии рака шейки матки коррелирует с уровнем экспрессии MKI67, CDKN2A, в частности CCNB1, BIRC5, AURKA; BCL2 или используют любые другие маркеры апоптоза, изменение уровня экспрессии которых при прогрессировании интраэпителиальной цервикальной неоплазии и развитии рака шейки матки коррелирует с уровнем экспрессии BCL2, в частности BAX, BAG1, NDRG1; PGR или используют любые другие маркеры рецепторного аппарата клеток, изменение уровня экспрессии которых при прогрессировании интраэпителиальной цервикальной неоплазии и развитии рака шейки матки коррелирует с уровнем экспрессии PGR, в частности ESR1, CD68, в образцах из мест поражений и полученные в ходе реакции значения уровней мРНК подставляют в формулу,где p - риск неопластической трансформации;z - значение регрессионной функции, определяют по формулеz=b1*Х1+b2*Х2+…+bn*Xn+а,где X1…Xn - уровень экспрессии мРНК генов или индекс соотношения уровня экспрессии генов; b1…bn - регрессионные коэффициенты; а - константа; при этом если значение p менее или равно пороговому значению (p≤cut-off), делают заключение об отсутствии риска малигнизации; если значение p>cut-off,делают заключение о прогрессии заболевания и высоком риске неопластической трансформации; пороговое значение определяют на основе экспериментальных данных с помощью ROC-анализа.A method for assessing the risk of progression of intraepithelial cervical neoplasia and the development of cervical cancer based on the determination of human gene mRNA levels, characterized in that the mRNA levels of human genes MKI67, CDKN2A are measured or any other markers of cell cycle proliferation and regulation are used, changes in the expression level of which with the progression of intraepithelial cervical neoplasia and the development of cervical cancer correlates with the expression level of MKI67, CDKN2A, in particular CCNB1, BIRC5, AURKA; BCL2 or use any other markers of apoptosis, the change in the expression level of which with the progression of intraepithelial cervical neoplasia and the development of cervical cancer correlates with the expression level of BCL2, in particular BAX, BAG1, NDRG1; PGR or use any other markers of the receptor apparatus of cells, the change in the expression level of which with the progression of intraepithelial cervical neoplasia and the development of cervical cancer correlates with the expression level of PGR, in particular ESR1, CD68, in the samples from the lesion sites and the values of mRNA obtained during the reaction are substituted into the formula, where p is the risk of neoplastic transformation; z is the value of the regression function, is determined by the formula z = b1 * X1 + b2 * X2 + ... + bn * Xn + a, where X1 ... Xn is the level of expression of the gene mRNA or the index of the ratio of the level of ex gene pressures; b1 ... bn - regression coefficients; a is a constant; in this case, if the p value is less than or equal to the threshold value (p≤cut-off), conclude that there is no risk of malignancy; if the value p> cut-off, make a conclusion about the progression of the disease and the high risk of neoplastic transformation; the threshold value is determined on the basis of experimental data using ROC analysis.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015103190A RU2660360C2 (en) | 2015-02-02 | 2015-02-02 | Method for assessing the risk of progression of intraepithelial cervical neoplasia and development of cervical cancer by determining the levels of human mrna genes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2015103190A RU2660360C2 (en) | 2015-02-02 | 2015-02-02 | Method for assessing the risk of progression of intraepithelial cervical neoplasia and development of cervical cancer by determining the levels of human mrna genes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015103190A true RU2015103190A (en) | 2016-08-20 |
| RU2660360C2 RU2660360C2 (en) | 2018-07-05 |
Family
ID=56694704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015103190A RU2660360C2 (en) | 2015-02-02 | 2015-02-02 | Method for assessing the risk of progression of intraepithelial cervical neoplasia and development of cervical cancer by determining the levels of human mrna genes |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2660360C2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2719581C1 (en) * | 2019-06-17 | 2020-04-21 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") | Method for predicting the risk of recurrence in hpv16-positive patients with squamous intraepithelial high-grade disease on the basis of determining the physical status of the virus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040248107A1 (en) * | 2003-06-09 | 2004-12-09 | Sokolova Irina A. | Detection of high grade dysplasia in cervical cells |
| RU2466392C2 (en) * | 2011-02-15 | 2012-11-10 | Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) | Method for prediction of cervical cancer in benign and pre-cancer cervical processes in females of reproductive age |
| RU2466390C2 (en) * | 2011-02-15 | 2012-11-10 | Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) | Method for prediction of developing endometrial cancer in pathological endometrial processes in females of reproductive age |
| RU2532344C2 (en) * | 2012-04-11 | 2014-11-10 | Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения и социального развития Российской Федерации | Diagnostic technique for hyperproliferative conditions and method for assessing risk of cervical cancer accompanying cervical intraepithelial neoplasia and papilloma virus carrier state by determinig mrna of functional human gene complex |
-
2015
- 2015-02-02 RU RU2015103190A patent/RU2660360C2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2660360C2 (en) | 2018-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Balain et al. | The Oswestry Risk Index: an aid in the treatment of metastatic disease of the spine | |
| MX2020001156A (en) | Method for the prognosis and treatment of cancer metastasis. | |
| Flores et al. | A new measure for gene expression biclustering based on non-parametric correlation | |
| Freedland et al. | Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy | |
| Boorjian et al. | Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer | |
| Huang et al. | Meta-analysis for cyclin E in lung cancer survival | |
| Hongo et al. | CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence | |
| JP2016500110A5 (en) | ||
| Scanzello et al. | Inflammatory activity in symptomatic knee osteoarthritis: not all inflammation is local | |
| RU2014112350A (en) | METHOD FOR DETECTING NUCLEOSOMES CONTAINING NUCLEOTIDES | |
| TW200730825A (en) | Method and apparatus for correlating levels of biomarker products with disease | |
| RU2008115113A (en) | GENE EXPRESSION PROFILING FOR IDENTIFICATION OF PROGNOSTIC SUBCLASSES IN NOSopharyngeal carcinoma | |
| NZ629074A (en) | Biomarkers for gastric cancer and uses thereof | |
| Liang et al. | Prognostic significance of PTEN, Ki-67 and CD44s expression patterns in gastrointestinal stromal tumors | |
| Lu et al. | Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314 | |
| WO2007146668A3 (en) | Use of imp3 as a prognostic marker for cancer | |
| RU2019104870A (en) | COMBINED TEST FOR THE PRESENCE OF COLORECTAL CANCER | |
| Xu et al. | Robust identification of gene-environment interactions for prognosis using a quantile partial correlation approach | |
| WO2018093236A3 (en) | Method for predicting prognosis of breast cancer patient | |
| RU2015103190A (en) | METHOD FOR ASSESSING THE RISK OF PROGRESSING INTRAEPITITAL CERVICAL NEOPLASIA AND THE DEVELOPMENT OF Cervical Cancer ON THE BASIS OF DETERMINING HUMAN GENE mRNA LEVELS | |
| JP6940920B2 (en) | Systems and methods for predicting drug-induced inotropic effects and risk of arrhythmia induction | |
| Klein et al. | Integrative analysis of multiple genomic variables using a hierarchical Bayesian model. | |
| Reis | Non-muscle invasive bladder cancer (NMIBC): boiling arena and promissory future | |
| Meskawi et al. | FG has no added value in prediction of mortality after partial and radical nephrectomy for chromophobe renal cell carcinoma patients | |
| CN111712713A (en) | Methods, devices and kits for early detection of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| HZ9A | Changing address for correspondence with an applicant | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180718 |